Vertex dubs blockbuster hep C drug Incivek; Neoprobe shot up on promising comparative data for its radiopharmaceutical;

 @FierceBiotech: Clinical, regulatory jobs top biotech's "must-hire" list. News | Follow @FierceBiotech

 @JohnCFierce: Every time a biotech gets back a partnered program, it's positioned as a big win. That sometimes happens (Exelixis), but it's no easy task. | Follow @JohnCFierce

> Vertex has come up with a commercial name for telaprevir, a blockbuster hepatitis C treatment that is likely to get an approval later this month from the FDA. The marketing masters at the company have settled on Incivek (pronounced in-see-vek). Report

> Shares of Neoprobe ($NEOP) shot up after the company announced yesterday evening that a late-stage study demonstrated that its radiopharmaceutical Lymphoseek is superior to the current standard for identifying cancerous lymph nodes. The company plans to seek regulatory approval in the third quarter. Report

> A day before its showdown with insurgent investors, Switzerland's Actelion says it will appeal a $547 million judgment in a case arising from its acquisition of CoTherix. Story

> Outsourcing-Pharma clarified just how big an impact Parexel's decision to restructure its early-phase work will have on the company. The CRO plans to lay off 300, but it also plans to hire up as many as 450 others during this quarter. Story

> The Dutch biotech ProFibrix announced the successful closing of a series B follow-on financing. ProFibrix release

> The Boston Globe has the latest piece on the industry's growing fondness for rare disease drugs. Novartis has been trying to open up fresh talks on the subject with academic and smaller biotechs in Boston this week. Story

> The FDA has approved Sun Pharma's application for Docefrez injection, which includes the chemical docetaxel. Analysts expect it to earn $50 million over a year. Story

Pharma News

@FiercePharma: Pfizer profits beat, but drug sales drop. Report | Follow @FiercePharma

> Comparative data absent for many new drugs. Story

> FTC chief laments 63% boost in generic settlements. Article

> GSK spends $120M-plus on Poligrip suits. Item

Drug Delivery News

> Nanovaults deliver drugs that kick-start the immune system against lung cancer. News

> India's Manipal College prepares for nanotech drug-delivery revolution. Story

> MicroDose's dry powder inhaler incorporated into Novartis device. Story

> MIT nanoparticle peels away layers of tumor entry. Article

> Thai researchers test brain cancer delivery system. Report

Medical Device News

> Boston Scientific alerts public about stolen shipment. Story

> Databases track patients with artificial knees, hips. Report

> NeuroVigil closes first round of financing. Item

> Nanostim signs investment deal with St. Jude. Article

> Baucus questions Medtronic over GPO contract cancellations. News

> Mazor gets good news in Europe on SpineAssist. Article

> Gene-therapy approach appears to work for AMD drug. Article

And Finally... The CDC reports that the number of Americans suffering from asthma spiked to 24.6 million in 2009, an increase of more than 4 million in nine years. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.